Sign in →

Test ID F5NGS F5 Gene, Next-Generation Sequencing, Varies


Ordering Guidance


If the patient appears to have a bleeding disorder, the clinical workup for factor V deficiency (F5D) begins with special coagulation testing for factor V activity. Order FACTV / Coagulation Factor V Activity Assay, Plasma.

 

If thrombophilia is the indication for testing, the vast majority (approximately 95%) of individuals with thrombophilia due to hereditary activated protein C resistance have a specific point alteration in the F5 gene called factor V Leiden (c.1601G>A, p.Arg534Gln; historically known as "R506Q" or "1691G>A"), which can be assayed directly and more cost-effectively by targeted alteration testing. If testing for factor V Leiden is desired instead of full-gene sequencing, order F5DNA / Factor V Leiden (R506Q) Mutation, Blood.



Shipping Instructions


Ambient and refrigerate specimens must arrive within 7 days of collection, and frozen specimens must arrive within 14 days.

 

Collect and package specimens as close to shipping time as possible.



Necessary Information


Rare Coagulation Disorder Patient Information is required. Testing may proceed without the patient information, however, the information aids in providing a more thorough interpretation. Ordering providers are strongly encouraged to fill out the form and send with the specimen.



Specimen Required


Submit only 1 of the following specimens:

 

Specimen Type: Whole blood

Container/Tube:

Preferred: Lavender top (EDTA)

Acceptable: Yellow top (ACD) or light-blue top (3.2% sodium citrate)

Specimen Volume: 3 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Send whole blood specimen in original tube. Do not aliquot.

Specimen Stability: Ambient (preferred)/Refrigerated/Frozen

 

Specimen Type: Extracted DNA

Container/Tube: 1.5- to 2-mL tube

Specimen Volume: Entire specimen

Collection Instructions:

1. Label specimen as extracted DNA and source of specimen.

2. Provide indication of volume and concentration of the DNA.

Specimen Stability: Frozen (preferred)/Refrigerated/Ambient


Forms

1. Rare Coagulation Disorder Patient Information (T824) is required.

2. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available.

-Informed Consent for Genetic Testing (T576)

-Informed Consent for Genetic Testing-Spanish (T826)

3. If not ordering electronically, complete, print, and send a Coagulation Test Request (T753) with the specimen.

Useful For

Genetic confirmation of factor V deficiency with the identification of an alteration in the F5 gene known or suspected to cause the condition

 

Carrier testing for close family members of an individual with a factor V deficiency diagnosis

 

This test is not intended to evaluate for the factor V Leiden mutation.

 

This test is not intended for prenatal diagnosis.

Genetics Test Information

This test detects pathogenic alterations in the F5 gene to delineate the underlying molecular defect in a patient with a laboratory diagnosis of coagulation factor V deficiency. This test may also detect rare alterations in F5 that cause activated protein C  resistance, resulting in thrombophilia.

 

The gene target for this test is:

Gene name (transcript): F5 (GRCh37 [hg19] NM_000130)

Chromosomal location: 1q23-24

Testing Algorithm

If bleeding is the reason for testing, genetic testing for factor V deficiency should only be considered if there is an isolated reduction of factor V activity in plasma using a specific prothrombin -based factor V assay(1) and acquired causes of a low factor V are excluded.

 

Genetic testing for F5D is indicated if:

-Factor V activity is reduced and acquired causes of FV deficiency have been excluded

-The FVIII activity is normal (low factor V levels with concurrently low factor VIII levels suggest combined deficiency of factor V and FVIII [F5F8D], a condition with a genetic etiology different from that of F5D)

 

If the patient appears to have thrombophilia, the results of an activated protein C (APC) resistance assay indicate presence of resistance to APC, and the factor V Leiden genotype does not correlate with the severity of thrombophilia or clinical presentation, full-gene sequencing of F5 may be warranted.

 

For more information of specific testing scenarios, see Ordering Guidance.

Method Name

Custom Sequence Capture and Targeted Next-Generation Sequencing (NGS) followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing when appropriate

Reporting Name

F5 Gene, Full Gene NGS

Specimen Type

Varies

Specimen Minimum Volume

Blood: 1 mL
Extracted DNA: 100 mcL at 50 ng/mcl concentration

Specimen Stability Information

Specimen Type Temperature Time Special Container
Varies Ambient (preferred) 7 days
  Frozen  14 days
  Refrigerated  7 days

Reference Values

An interpretive report will be provided

Day(s) Performed

Varies

Report Available

21 to 28 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

81479

LOINC Code Information

Test ID Test Order Name Order LOINC Value
F5NGS F5 Gene, Full Gene NGS 94236-7

 

Result ID Test Result Name Result LOINC Value
113027 F5NGS Result 50397-9
113021 Alterations Detected 82939-0
113020 Interpretation 69047-9
113022 Additional Information 48767-8
113023 Method 85069-3
113024 Disclaimer 62364-5
113025 Panel Gene List 21669-7
113026 Reviewed By 18771-6

NY State Approved

Yes